Citations

Showing 10 of 108152 citations.

Gastric per-oral endoscopic myotomy (G-POEM) for the treatment of gastric sleeve stenosis: a feasibility and safety study
Zhang, Linda Y. , Schweitzer, Michael , Khashab, Mouen A. , Kumbhari, Vivek , Canto, Marcia Irene

Mayo Clinic

Endoscopy | July 5, 2021 | Volume: 54 | Issue: 04 | Pages: 376-381

10.1055/a-1544-4923 | PMID 34225370 Get It

Abstract Background Traditional endoscopic treatments have limited success in gastric sleeve stenosis (GSS). Gastric peroral endoscopic myotomy (G-POEM) could conceivably obliterate the twist/angulation that causes GSS through a tunneled stricturotomy. We report early outcomes of G-POEM for GSS treatment. Methods We retrospectively reviewed all patients with GSS treated with G-POEM at our center. The primary end point was clinical success, defined as symptom improvement with resumption of adequate oral intake, without requiring further intervention. Results 13 patients (mean age 43 ± 10.9 years; 12 female) underwent G-POEM for predominantly helical (11/13, 85 %) GSS. Three (23 %) had concurrent sleeve leak and 10 (77 %) had prior GSS treatment. Two intraoperative complications occurred, with no deviation to the procedure; no major complications occurred. At median follow-up of 175 (interquartile range [IQR] 119–260) days, clinical success was achieved in 10 patients (77 %). Median Gastroparesis Cardinal Symptom Index score in responders decreased from 2.06 (IQR 1.5–2.8) to 0.39 (IQR 0.2–0.5). Three patients (23 %) required surgical revision. Conclusions G-POEM was feasible and safe, and may provide an alternative option for those averse to undergoing surgical revision for treatment of GSS.
Pre-analytical considerations in biomarker research: focus on cardiovascular disease
Revuelta‐López, Elena , Barallat, Jaume , Cserkóová, Adriana, Gálvez‐Montón, Carolina , Jaffe, Allan S. , Bayés‐Genís, Antoni , Jaffe, Allan S. , Januzzi, James Louis

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | July 5, 2021 | Volume: 59 | Issue: 11 | Pages: 1747-1760

10.1515/cclm-2021-0377 | PMID 34225398 Get It

Abstract Clinical biomarker research is growing at a fast pace, particularly in the cardiovascular field, due to the demanding requirement to provide personalized precision medicine. The lack of a distinct molecular signature for each cardiovascular derangement results in a one-size-fits-all diagnostic and therapeutic approach, which may partially explain suboptimal outcomes in heterogeneous cardiovascular diseases (e.g., heart failure with preserved ejection fraction). A multidimensional approach using different biomarkers is quickly evolving, but it is necessary to consider pre-analytical variables, those to which a biological sample is subject before being analyzed, namely sample collection, handling, processing, and storage. Pre-analytical errors can induce systematic bias and imprecision, which may compromise research results, and are easy to avoid with an adequate study design. Academic clinicians and investigators must be aware of the basic considerations for biospecimen management and essential pre-analytical recommendations as lynchpin for biological material to provide efficient and valid data.
Demographics and Clinical Outcomes in Patients Older Than 75 Years Treated for Acute Venous Thromboembolism
Chaudhary, Rahul , Loganathan, Danekka, Vlazny, Danielle T. , Casanegra, Ana I. , Froehling, David A. , Peterson, Lisa , Hodge, David O. , Peterson, Lisa G, McBane, Robert D. , Casanegra, Ana I , Loganathan, Danekka, Houghton, Damon E. , Wysokiński, Waldemar E.

Mayo Clinic

American Journal of Therapeutics | July 5, 2021 | Volume: 29 | Issue: 1 | Pages: e151-e153

10.1097/mjt.0000000000001389 | PMID 34994355 Get It

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Beitinjaneh, Amer, Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Kochenderfer, James N., Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M., Lin, Yi , Beitinjaneh, Amer , Kochenderfer, James N. , Brown, Anne Rain , De Moraes, Alice Gallo, Lin, Yi , Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M.

Mayo Clinic

Critical Care Medicine | July 5, 2021 | Volume: 50 | Issue: 1 | Pages: 81-92

10.1097/ccm.0000000000005149 | PMID 34259446 Get It

OBJECTIVES: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. DESIGN: Retrospective cohort study SETTING: Nine centers across the U.S. part of the chimeric antigen receptor-ICU initiative. PATIENTS: Adult patients treated with chimeric antigen receptor T-cell therapy who required ICU admission between November 2017 and May 2019. INTERVENTIONS: Demographics, toxicities, specific interventions, and outcomes were collected. RESULTS: One-hundred five patients treated with axicabtagene ciloleucel required ICU admission for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome during the study period. At the time of ICU admission, the majority of patients had grade 3–4 toxicities (66.7%); 15.2% had grade 3–4 cytokine release syndrome and 64% grade 3–4 immune effector cell-associated neurotoxicity syndrome. During ICU stay, cytokine release syndrome was observed in 77.1% patients and immune effector cell-associated neurotoxicity syndrome in 84.8% of patients; 61.9% patients experienced both toxicities. Seventy-nine percent of patients developed greater than or equal to grade 3 toxicities during ICU stay, however, need for vasopressors (18.1%), mechanical ventilation (10.5%), and dialysis (2.9%) was uncommon. Immune Effector Cell-Associated Encephalopathy score less than 3 (69.7%), seizures (20.2%), status epilepticus (5.7%), motor deficits (12.4%), and cerebral edema (7.9%) were more prevalent. ICU mortality was 8.6%, with only three deaths related to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Median overall survival time was 10.4 months (95% CI, 6.64–not available mo). Toxicity grade or organ support had no impact on overall survival; higher cumulative corticosteroid doses were associated to decreased overall and progression-free survival. CONCLUSIONS: This is the first study to describe a multicenter cohort of patients requiring ICU admission with cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Despite severe toxicities, organ support and in-hospital mortality were low in this patient population.
Symmetric eruption of the elbows in a pediatric patient
Sokumbi, Olayemi , Turbeville, Jackson, Sokumbi, Olayemi

Mayo Clinic

Pediatric Dermatology | July 5, 2021 | Volume: 38 | Issue: 3 | Pages: No page available

10.1111/pde.14561 | PMID 34224611 Get It

Impact of a Devastating Patient Complication on the Aesthetic Plastic Surgeon
Bernard, Robert W.

Mayo Clinic

Aesthetic Surgery Journal | July 5, 2021 | Volume: 41 | Issue: 11 | Pages: 1335-1337

10.1093/asj/sjab271 | PMID 34223878 Get It

Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States
Wijarnpreecha, Karn , Li, Fang , Xiang, Yang , Zhu, Cong , Maroufy, Vahed , Tao, Wei , Pham, Huy Anh, Zhou, Yujia , Li, Jianfu , Zhang, Xinyuan , Xu, Hua , Tao, Cui , Xu, Hua , Taner, C. Burcin , Tao, Cui , Wijarnpreecha, Karn , Li, Fang , Xu, Xun, Wang, Qing , Tao, Wei, Dang, Yifang , Yang, Liu

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 5, 2021 | Volume: 54 | Issue: 4 | Pages: 481-492

10.1111/apt.16490 | PMID 34224163 Get It

SummaryBackgroundPrevious studies have demonstrated an association between nonselective beta‐blockers (NSBBs) and lower risk of hepatocellular carcinoma (HCC) in cirrhosis. However, there has been no population‐based study investigating the risk of HCC among cirrhotic patients treated using carvedilol.AimsTo determine the risk of HCC among cirrhotic patients with NSBBs including carvedilol.MethodsThis retrospective cohort study utilised the Cerner Health Facts database in the United States from 2000 to 2017. Kaplan‐Meier estimate, Cox proportional hazards regression, and propensity score matching (PSM) were used to test the HCC risk among the carvedilol, nadolol, and propranolol groups compared with no beta‐blocker group.ResultsThe final cohort comprised 107 428 eligible patients. The 100‐month cumulative HCC incidence of NSBBs was significantly lower than the no beta‐blocker group (carvedilol (11.24%) vs no beta‐blocker (15.69%), nadolol (27.55%) vs no beta‐blocker (32.11%), and propranolol (26.17%) vs no beta‐blocker (28.84%) (P values < 0.0001). NSBBs were associated with a significantly lower risk of HCC (Hazard ratio: carvedilol 0.61 (95% CI 0.51‐0.73), nadolol 0.74 (95% CI 0.63‐0.87), propranolol 0.75 (95% CI 0.66‐0.84) after PSM in the multivariate cox analysis. In subgroup analysis, NSBBs reduced the risk of HCC in cirrhosis with complications and non‐alcoholic cirrhosis.ConclusionsNSBBs, including carvedilol, were associated with a significantly decreased risk of HCC in patients with cirrhosis when compared with no beta‐blocker regardless of complications status. Future randomised‐controlled studies comparing the incidence of HCC among NSBBs should elucidate which NSBB would be the best option to prevent HCC in cirrhosis.
Normalized intraplaque hemorrhage signal on MP-RAGE as a marker for acute ischemic neurological events
Larson, Anthony S. , Brinjikji, Waleed , Kroll, Neil J, Savastano, Luis , Benson, John C. , Larson, Anthony , Huston, John

Mayo Clinic

The Neuroradiology Journal | July 5, 2021 | Volume: 35 | Issue: 1 | Pages: 112-118

10.1177/19714009211029263 | PMID 34224247 Get It

Purpose This study sought to validate whether the signal intensity ratio (SIR) of carotid intraplaque hemorrhage (IPH) was associated with acute ischemic neurologic events. Methods A retrospective review was completed of consecutive patients that underwent neck magnetic resonance angiography using magnetization prepared-rapid gradient echo (MP-RAGE) and T1-CUBE sequences between 2017 and 2020. Patients with magnetic resonance evidence of IPH were included. SIRs were measured by comparing the maximum IPH signal with the mean intramuscular signal from the adjacent sternocleidomastoid. Patients were stratified into ischemic or non-ischemic groups based on the presence of acute ipsilateral ischemic events (stroke, retinal artery occlusion). Logistic regression analysis was performed to determine if increasing IPH SIR was associated with an increased risk of ipsilateral ischemic events. Results Of 85 included patients (85 arteries), 66 were male (77.6%). Mean age was 71.0 (SD ± 11.1). There were 70 arteries with IPH that were ipsilateral to an ischemic event, and 15 that belonged to patients without an ischemic event. No association was found between increasing IPH SIR seen on MP-RAGE (odds ratio (OR): 0.82; 95% confidence interval (CI): 0.58–1.4; P = 0.43) or T1-CUBE sequences (OR: 0.85; 95% CI: 0.53–1.5; P = 0.56). Conclusions There was no association between the SIR of IPH and acute ischemia on either MP-RAGE or T1-CUBE sequences. Further investigation is required prior to widespread acceptance of SIR as a predictive imaging marker of symptomatic carotid plaque.
A proposed framework for cerebral venous congestion
Arun, Anirudh , Higgins, Nicholas , Brinjikji, Waleed , Sattur, Mithun G. , Luciano, Mark G. , Meng, Ran , Satti, Sudhakar R , Amans, Matthew R. , Nakaji, Peter , Huisman, Thierry A.G.M. , Moghekar, Abhay , Mendes Pereira, Vitor , Fargen, Kyle M , Hui, Ferdinand

Mayo Clinic

The Neuroradiology Journal | July 5, 2021 | Volume: 35 | Issue: 1 | Pages: 94-111

10.1177/19714009211029261 | PMID 34224274 Get It

Background While venous congestion in the peripheral vasculature has been described and accepted, intracranial venous congestion remains poorly understood. The characteristics, pathophysiology, and management of cerebral venous stasis, venous hypertension and venous congestion remain controversial, and a unifying conceptual schema is absent. The cerebral venous and lymphatic systems are part of a complex and dynamic interaction between the intracranial compartments, with interplay between the parenchyma, veins, arteries, cerebrospinal fluid, and recently characterized lymphatic-like systems in the brain. Each component contributes towards intracranial pressure, occupying space within the fixed calvarial volume. This article proposes a framework to consider conditions resulting in brain and neck venous congestion, and seeks to expedite further study of cerebral venous diagnoses, mechanisms, symptomatology, and treatments. Methods A multi-institution retrospective review was performed to identify unique patient cases, complemented with a published case series to assess a spectrum of disease states with components of venous congestion affecting the brain. These diseases were organized according to anatomical location and purported mechanisms. Outcomes of treatments were also analyzed. Illustrative cases were identified in the venous treatment databases of the authors. Conclusion This framework is the first clinically structured description of venous pathologies resulting in intracranial venous and cerebrospinal fluid hypertension. Our proposed system highlights unique clinical symptoms and features critical for appropriate diagnostic work-up and potential treatment. This novel schema allows clinicians effectively to approach cases of intracranial hypertension secondary to venous etiologies, and furthermore provides a framework by which researchers can better understand this developing area of cerebrovascular disease.